No abstract available
MeSH terms
-
Aged
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Benzamides
-
Dasatinib
-
Drug Resistance, Neoplasm
-
Humans
-
Imatinib Mesylate
-
Male
-
Piperazines / administration & dosage
-
Piperazines / adverse effects
-
Piperazines / therapeutic use*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
-
Protein Kinase Inhibitors / administration & dosage
-
Protein Kinase Inhibitors / adverse effects
-
Protein Kinase Inhibitors / therapeutic use
-
Pyrimidines / administration & dosage
-
Pyrimidines / adverse effects
-
Pyrimidines / therapeutic use*
-
Remission Induction
-
Renal Insufficiency / complications*
-
Thiazoles / administration & dosage
-
Thiazoles / adverse effects
-
Thiazoles / therapeutic use*
Substances
-
Antineoplastic Agents
-
Benzamides
-
Piperazines
-
Protein Kinase Inhibitors
-
Pyrimidines
-
Thiazoles
-
Imatinib Mesylate
-
Dasatinib